UAE grants ImmunityBio's Anktiva broad approval for bladder and lung cancer
IBRX ImmunityBio Inc
$7.45 +9.08%
차트·분석 보기 → - 1ImmunityBio (IBRX) shares rose about 8% Wednesday night after the UAE approved Anktiva for broad use in bladder and metastatic lung cancer
- 2For bladder, the approval covers the full range of BCG-unresponsive cases including papillary-only disease; for lung, it targets metastatic non-small cell lung cancer that has progressed after standard treatment
- 3The UAE became the first in the world to open the full bladder indication, while the US decision on the papillary-only expansion is targeted for January 6, 2027
This 3-line summary is compiled from the report below.
Stocktwits +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다